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The Swiss approach to the COVID-19 outbreak
To the Editor:
Angelico et al. described the impact of the novel coronavirus (COVID-19) outbreak on organ 
transplantation in Italy (1), where only one center in Milan has limited transplant activity to most 
urgent cases. The rest of the country continued with the regular allocation policy (1). In 
Switzerland, which has more COVID-19 cases per capita than Italy (2), we have opted for a 
stepwise approach (3):
1) Stop live donor transplantations;
2) Stop pancreas and islet transplants;
3) Stop deceased donor kidney transplants;
4) A tailored approach to urgent status transplants;
5) Only urgent transplants to be performed;
6) Stop all transplants.
In Geneva, a regional hotspot (2), we halted all transplantation activity, except for urgent cases 
(level 5). Less affected centers have continued their activity at level 4 (Table 1). Overall, the 
number of transplanted organs in March has decreased to 26 (-38% compared to the monthly 
average of 2019). Our projections indicate a 26% decrease of the transplantation activity in 2020 
(estimated 368 vs. 501 organs in 2019). Between February and March 2020, the decrease in 
transplantations already led to an increase in median waiting time of 21.2% and 40.2% for kidney 
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This development is concerning on two levels. Firstly, the increase in waiting time will likely 
increase the waitlist mortality after the pandemic. This raises the question whether it is ethical to 
trade-off immediate COVID-19-related mortality for a projected increase in waitlist mortality. 
Jeopardizing the survival of patients on the waiting list cannot be an acceptable long-term option 
but might be inevitable in the short-term. In extreme situations, requiring triage of resources, 
delaying access to a life-saving organ is also a triage decision. However, a staged resumption of 
transplantation activity, once the pandemic has reached a plateau, is essential. Secondly, in a 
setting where transplantation activity is significantly reduced, patients with a Model End Stage 
Liver Disease (MELD) exception will inevitably gain points merely by waiting. It is crucial to 
avoid putting patients with a true laboratory MELD at a disadvantage in the post-COVID-19 
period.
Regarding testing, we disagree that it should be limited to areas affected by COVID-19 (5). The 
past few weeks have shown how dynamic the epidemiological situation is. We cannot take risks 
and expose transplanted patients to an unknown hazard. In the current setting, we would prefer to 
transplant patients who already developed an immunity against SARS CoV2, as they are likely 
protected against COVID-19 in the short term. We therefore advocate for serological testing of 
waitlisted patients and wide molecular testing of all patients immediately before transplantation. 
However, one also needs to consider the limitations of serological testing, of which the specificity 
(cross-reactivity with other coronaviruses) and sensitivity still have to be determined.
Overall, we suggest the decision to halt transplantation activity must be integrated in a global 
public health perspective and taken only when absolutely necessary. Furthermore, we advocate for 
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Table
Table 1. Impact of the COVID-19 pandemic on liver transplantation activity in 
Switzerland
Change of transplantation 
activity in March 2020*
COVID Infection 
rate (1, 2) +
Patients in ICU care 
(2) ++
Geneva -100% 8,441 94.19
Zurich -6% 1,905 32.83
Bern -50% 1,290 31.88
Italy -25% 2,307 66.16
*Compared to the average monthly number of liver transplantations in 2019, +Confirmed 
cases/million inhabitants, ++Patients treated in ICU/million inhabitants
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